About this medicine

Doxazosin is primarily a cardiovascular and urinary medicine. Being included in a psychiatric reference does not mean it is licensed or routinely recommended for a psychiatric condition.

What is this medicine used for?

Cardura's licensed uses are hypertension and symptoms of benign prostate enlargement. The checked record does not include PTSD or nightmares; no UK psychiatric dosing schedule is inferred from US content.

Cardura XL and SyriMed suspension also list hypertension and benign prostatic hyperplasia, not PTSD or nightmares. Neither a slower release system nor a liquid concentration adds a psychiatric authorisation.

Which warning signs need help?

Severe allergy, chest pain with collapse, stroke symptoms or a persistent painful erection requires urgent medical help. An overdose may cause dangerous low blood pressure. Use emergency services for your actual location.

Fainting is especially relevant after starting or increasing treatment. Sit or lie down if suddenly dizzy and obtain advice. A prolonged painful erection needs urgent medical attention; tell the eye surgeon about current or previous use before cataract surgery.

How do I take it safely?

For checked standard Cardura, clinicians generally start at 1 mg daily and increase at one- to two-week intervals. Licensed maximums differ: 16 mg for hypertension and 8 mg for prostate symptoms. These are not psychiatric treatment instructions.

Cardura XL comes in 4 and 8 mg prolonged-release tablets. Its reference begins at 4 mg once daily and allows an increase to 8 mg after assessing response, which may take four weeks. Swallow whole with liquid; do not crush, chew or divide. An empty shell can appear in stools.

SyriMed suspension is 0.4 mg/mL, not a prolonged-release liquid. Its reference begins at 1 mg once daily for either licensed indication. Shake for at least 30 seconds before measuring; use the supplied 10 mL syringe for volumes up to 10 mL and 20 mL syringe for larger volumes. Discard 30 days after opening.

A formulation change needs a prescribing plan and blood-pressure review. NHS SPS describes several clinician-selected strategies, not one universal milligram conversion. Do not replace tablets with a matching-looking volume or change from XL on your own.

What side effects should I know about?

Headache, dizziness, ankle swelling and stomach upset can occur. Tell a pharmacist or doctor if symptoms persist; do not assume a faint feeling is simply anxiety.

Who needs extra care with this medicine?

A history of postural hypotension and certain bladder-outflow conditions are exclusions. Tell the eye surgeon about current or previous alpha-blocker use before cataract surgery.

Cardura XL has additional restrictions for previous gastrointestinal or oesophageal obstruction or narrowing, because of its non-deformable release system. This is not a reason to apply the same physical-tablet restriction to the suspension.

Can it affect my other medicines?

Sildenafil and similar medicines, other blood-pressure treatments and strong enzyme inhibitors can increase low-blood-pressure risk. Alcohol can worsen dizziness; check non-prescription products too.

Medicines for erectile difficulties can add to blood-pressure lowering. Do not manage this by guessing a dose interval; the clinician should assess stability, doses and symptoms.

What check-ups will I need?

Review blood pressure, postural symptoms and falls when starting, changing dose or changing formulation. For prostate symptoms, assessment should exclude other causes such as malignancy.

After switching from XL to standard tablets, monitor for either a blood-pressure rise or an excessive fall; the new regimen may need adjustment. NHS SPS guidance concerns clinician-managed switching, not a self-treatment schedule.

What about pregnancy, breastfeeding and age?

Safety and efficacy in children are not established for the checked XL and suspension products. Their pregnancy and breastfeeding wording requires the prescriber to judge benefit against risk; low reported milk transfer does not establish absence of infant risk.

Liver impairment requires particular caution. The suspension contains parabens, which can cause delayed allergic reactions, as well as propylene glycol and benzoic acid. Excipients and ability to swallow matter when choosing a formulation.

What if I miss a dose or want to stop?

Do not double a missed dose or stop a regular prescription without advice. Follow the leaflet for your exact product, because immediate- and modified-release instructions differ.

How does it work?

Doxazosin helps certain muscles relax, including muscle in blood-vessel walls and around the bladder outlet. This can lower blood pressure and make it easier for urine to flow. It does this by blocking part of the body’s response to norepinephrine, a chemical messenger also called noradrenaline.

How Brain Cells Communicate

Norepinephrine carries messages between nerve cells and helps control how organs respond to activity and stress. Receptors are proteins that receive these messages. One type, called alpha-1, helps control smooth muscle: muscle that works without conscious effort in places such as blood-vessel walls. The term adrenergic refers to this family of chemical signals and receptors.

What is known: Alpha-1 signals can make smooth muscle tighten.

What remains uncertain: These signals alone cannot explain why a particular person has nightmares.

Norepinephrine: Alpha-1 adrenergic receptor

A messenger acts at a solid membrane receptor; protein coupling inside the cell illustrates a signaling response, rather than passage through an ion pore. Messenger: Norepinephrine Target: Alpha-1 adrenergic receptor Cell context: smooth-muscle cell; simplified membrane, not a binding structure.
  1. Messenger

    Norepinephrine

  2. Target

    Alpha-1 adrenergic receptor

  3. Cell context

    smooth-muscle cell; simplified membrane, not a binding structure.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Norepinephrine can activate alpha-1 adrenergic receptor and change signaling in the cell. This is a smooth-muscle cell example, not a complete nervous-system pathway.

Alpha-1 signals can make smooth muscle tighten. Simplified illustration of the process; individual responses vary.
About this illustration

Norepinephrine; Alpha-1 receptor; Muscle tone. These signals alone cannot explain why a particular person has nightmares.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How the Medication Changes Signaling

Doxazosin blocks alpha-1 receptors, reducing the tightening signal. This blocking action is called antagonism. Less muscle tone, or tension in the muscle, means the vessels can relax and blood flows with less resistance.

Relaxation around the bladder outlet and prostate can also help urine pass. The prostate is a gland around the tube that carries urine out of the bladder; doxazosin’s effect on this muscle does not mean it shrinks the gland. These are peripheral effects, meaning effects outside the brain and spinal cord.

What is known: Alpha-1 blockade helps explain the effects on blood pressure and urine flow.

What remains uncertain: Those effects do not establish whether it will help with nightmares after trauma.

Doxazosin: Alpha-1 adrenergic receptor

A receptor with natural messenger and a separate terracotta medicine symbol above the membrane; intracellular proteins illustrate the downstream signaling context. Messenger: Norepinephrine Target: Alpha-1 adrenergic receptor Doxazosin: receptor activation opposed: The medicine symbol and crossbar indicate antagonist action in a smooth-muscle cell; receptor action does not predict an individual clinical response.
  1. Messenger

    Norepinephrine

  2. Target

    Alpha-1 adrenergic receptor

  3. Doxazosin: receptor activation opposed

    The medicine symbol and crossbar indicate antagonist action in a smooth-muscle cell; receptor action does not predict an individual clinical response.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Doxazosin blocks alpha-1 adrenergic receptors. This smooth-muscle example explains a peripheral action; it does not establish nightmare-treatment benefit.

Alpha-1 blockade helps explain the effects on blood pressure and urine flow. Simplified illustration of the process; individual responses vary.
About this illustration

Doxazosin; Alpha-1 blockade; Less constriction. Those effects do not establish whether it will help with nightmares after trauma.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

A Closer Look at the Molecular Level

The original doxazosin molecule does most of the work in lowering blood pressure. The body also makes breakdown products, called metabolites, but their contribution appears small. How much medicine reaches a receptor and how the surrounding tissue responds both matter. A receptor interaction measured in a laboratory cannot, by itself, predict a person’s experience of treatment.

What is known: Doxazosin reduces receptor activation rather than copying the usual messenger’s action.

What remains uncertain: Its proposed role in trauma-related sleep problems needs separate clinical evidence.

How the process works

  1. Receptor binding
  2. Tissue response
  3. Clinical assessment
Doxazosin reduces receptor activation rather than copying the usual messenger’s action. Simplified illustration of the process; individual responses vary.
About this illustration

Receptor binding; Tissue response; Clinical assessment. Its proposed role in trauma-related sleep problems needs separate clinical evidence.

This is a simplified illustration. It does not show exactly how a medicine fits into a protein or predict a dose or response to treatment.

How does it affect my body?

Blood pressure may fall on standing, especially when starting treatment. Dizziness can cause falls; sit or lie down if faint and avoid hazardous activity while affected.

How does my body process it?

The liver extensively metabolises doxazosin, with CYP3A4 a major pathway. Its approximately 22-hour half-life supports once-daily dosing; liver impairment can increase exposure.

Cardura XL releases the medicine gradually, producing a later, lower peak than standard tablets. Both can be prescribed once daily, but the shared elimination half-life does not make their starting doses identical.

How do treatment options differ?

Cardura and prolonged-release doxazosin are not automatically interchangeable schedules. A shared alpha-blocking mechanism with prazosin is not proof of identical evidence, duration or dosing.

NHS England policy, explained by NHS SPS, does not support routine XL prescribing in primary care and favours standard tablets when appropriate. This is a prescribing-policy distinction, not withdrawal of the XL licence, nor a claim that every UK nation uses the same formulary policy.

A closer look at the science

Selective blockade of post-junctional alpha-1 adrenoceptors reduces the response to adrenergic signalling. This mechanism alone cannot establish efficacy for trauma-related symptoms.

The medicine contains doxazosin mesylate, a salt of the active doxazosin molecule. The neutral parent belongs to the quinazoline family and is not a benzodiazepine.

Chemical formula: C23H25N5O5 · CH4O3S

The portion before the dot is doxazosin: 23 carbon, 25 hydrogen, 5 nitrogen and 5 oxygen atoms. The dot separates the methanesulfonic-acid component in the label’s salt formula. Tablet strengths are expressed as equivalent doxazosin, not the total salt weight.

PubChem 2D depiction of neutral doxazosin; salt components omitted.
NCBI PubChem CID 3157. Lines are bonds; unlabeled corners are carbon and many hydrogen atoms are omitted. This neutral-parent drawing is connectivity, not a binding pose.

This verified PubChem neutral-parent drawing omits the mesylate component. It does not show a receptor-bound pose, establish brain exposure, or distinguish the tablet release systems.

How was this medicine developed?

The current Cardura information retains established cardiovascular and urinary indications. A medicine's later off-label discussion does not rewrite the history or scope of its marketing authorisation.

Sources and References

  1. Cardura 1 mg tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  2. Cardura 1 mg and 2 mg tablets: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  3. Doxazosin

    Scope: UK patient information.

  4. Cardura XL 4 mg prolonged-release tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  5. Cardura XL 8 mg prolonged-release tablets: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  6. Doxazosin 0.4 mg/mL oral suspension: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  7. Switching doxazosin XL tablets to doxazosin standard tablets

    Scope: England: NHS England prescribing-policy context; professional formulation guidance.

  8. Doxazosin tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action..

  9. Doxazosin: patient information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Why is this medication prescribed?..

  10. Cardura immediate-release: current US prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  11. Cardura XL: current US prescribing information

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  12. Richards and colleagues: randomized doxazosin trial for posttraumatic dreams and sleep, 2025

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  13. Doxazosin: verified neutral parent, PubChem CID 3157

    Scope: Shared science only; original source jurisdiction retained in title/publisher.

  14. Low blood pressure: MedlinePlus Medical Encyclopedia

Shared scientific background. US product pharmacology and international chemical references do not establish UK licences, doses, formulations or NHS recommendations.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top